Is the Options Market Predicting a Spike in QuidelOrtho Stock?

Investors need to pay close attention to QDEL stock based on the movements in the options market lately.

Zacks Investment Research • Jun 12, 2026

QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk

QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.

Zacks Investment Research • Jun 3, 2026

QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy.

PRNewsWire • Jun 2, 2026

When Blood Compatibility Becomes a Pregnancy Risk

SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation.

PRNewsWire • May 21, 2026

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026 Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m.

PRNewsWire • May 20, 2026

Hantavirus outbreak: these 3 stocks are poised to rip higher

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.

Invezz • May 12, 2026

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y

QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.

Zacks Investment Research • May 6, 2026

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ― ― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ― ― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

PRNewsWire • May 5, 2026